methyl 3-chloro-5-fluoro-4-nitrobenzoate | 2387035-92-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-chloro-5-fluoro-4-nitrobenzoate
• CAS: 2387035-92-7
• 化学式: C₈H₅ClFNO₄
• 分子量: 233.583
• InChiKey: CVBAAQSETGBELZ-UHFFFAOYSA-N

反应信息

• 作为反应物：
  描述：

  methyl 3-chloro-5-fluoro-4-nitrobenzoate 在 10% Pt/activated carbon 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 17.0~60.0 ℃ 、101.33 kPa 条件下， 反应 16.0h， 生成 methyl 4-amino-3-chloro-5-((2-(2-methyl-1H-imidazol-1-yl)ethyl)amino)benzoate
  参考文献：
  名称：

  [EN] CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AND OCTAHYDROFURO[3,4- B]PYRAZINES AS GLP-1 RECEPTOR MODULATORS
  [FR] CERTAINS 2,5-DIAZABICYCLO[4.2.0]OCTANES ET OCTAHYDROFURO[3,4-B]PYRAZINES UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR GLP-1

  摘要：

  There are disclosed certain 2,5-diazabicyclo[4.2.0]octanes of formula (I) and octahydrofuro[3,4-b]pyrazines, and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are GLP-1 receptor modulators and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions, for example Type 2 diabetes.

  公开号：

  WO2023057429A1
• 作为产物：
  描述：

  4-氨基-3-氟苯羧酸甲酯 在 sodium perborate 、 N-氯代丁二酰亚胺 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 methyl 3-chloro-5-fluoro-4-nitrobenzoate
  参考文献：
  名称：

  [EN] GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF
  [FR] MODULATEURS DU RÉCEPTEUR DU PEPTIDE-1 SIMILAIRE AU GLUCAGON ET LEURS UTILISATIONS

  摘要：

  Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods related to agonists of glucagon-like peptide-1 receptor (GLP-1R). In particular, the compounds and compositions may be used to treat GLP-1R-related disorders and conditions, including, e.g., obesity, T2DM, NAFLD, NASH as disclosed herein.

  公开号：

  WO2023001237A1

文献信息

• [EN] CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AS GLP-1 RECEPTOR MODULATORS<br/>[FR] CERTAINS 2,5-DIAZABICYCLO[4.2.0]OCTANES UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR GLP-1
  申请人：[en]ASTRAZENECA AB

  公开号：WO2023057427A1

  公开（公告）日：2023-04-13

  There are disclosed certain 2,5-diazabicyclo[4.2.0]octanes of formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are GLP-1 receptor modulators and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions, for example Type 2 diabetes.
• [EN] CERTAIN OCTAHYDROFURO[3,4- B]PYRAZINES AS GLP-1 RECEPTOR MODULATORS<br/>[FR] CERTAINES OCTAHYDROFURO 3,4-B]PYRAZINES UTILISÉES EN TANT QUE MODULATEURS DU RÉCEPTEUR GLP-1
  申请人：[en]ASTRAZENECA AB

  公开号：WO2023057414A1

  公开（公告）日：2023-04-13

  There are disclosed certain octahydrofuro[3,4-b]pyrazines of formula (la), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are GLP-1 receptor modulators and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions, for example Type 2 diabetes.
• [EN] CERTAIN 3-AZABICYCLO[3.1.0]HEXANES AS GLP-1 RECEPTOR MODULATORS<br/>[FR] CERTAINS 3-AZABICYCLO[3.1.0] HEXANES UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR DE GLP-1
  申请人：[en]ASTRAZENECA AB

  公开号：WO2023111145A1

  公开（公告）日：2023-06-22

  There are disclosed certain 3-azabicyclo[3.1.0]hexanes, and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are GLP-1 receptor modulators and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions, for example Type 2 diabetes.